Denali Therapeutics has been granted a patent for crystalline forms of a specific compound, along with the process of preparation and methods of use in pharmaceutical compositions. The patent includes six different forms of the compound, each designated by a letter. GlobalData’s report on Denali Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Denali Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Denali Therapeutics's grant share as of May 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline forms of pharmaceutical compound
A recently granted patent (Publication Number: US11999750B2) discloses various crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, including Forms A, B, and C. These forms are characterized by specific X-ray powder diffraction patterns and differential scanning calorimetry curves, making them distinct and identifiable. The patent also details a method for treating diseases or disorders mediated by RIPK1 by administering an effective amount of the crystalline form, targeting a wide range of conditions such as inflammatory bowel disease, rheumatoid arthritis, autoimmune hepatitis, Alzheimer's disease, and various other autoimmune and inflammatory conditions.
The patent claims outline the unique characteristics of each crystalline form, providing a basis for their identification and differentiation. The method described for treating RIPK1-mediated diseases showcases the potential therapeutic applications of these forms in addressing a diverse range of conditions, from autoimmune disorders to neurodegenerative diseases. The specificity and efficacy of these crystalline forms in targeting RIPK1-mediated diseases highlight their potential as novel treatment options for various challenging medical conditions, paving the way for further research and development in the field of pharmaceuticals and personalized medicine.
To know more about GlobalData’s detailed insights on Denali Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
